Non–small-cell Lung Cancer With Brain Metastasis at Presentation
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
&NA; Data on prevalence of brain metastases at presentation in patients with non–small‐cell lung cancer are limited. We queried the National Cancer Data Base to determine prevalence, risk factors and outcomes of patients with non–small‐cell lung cancer, presenting with brain metastases. Brain metastases were observed in 10.4% of patients, with median survival of 6 months. Risk of brain metastases at presentation may be calculated using 5 clinical variables. Background: Data on the prevalence of brain metastases at presentation in patients with non–small‐cell lung cancer (NSCLC) are limited. We queried the National Cancer Data Base to determine prevalence, clinical risk factors, and outcomes of patients with NSCLC presenting with brain metastases. Patients and Methods: Patients with NSCLC diagnosed between 2010 and 2012 were identified using the National Cancer Data Base. The risk of brain metastases for individual variables was summarized by odds ratios and calculated using logistic regression analysis. The Kaplan‐Meier product limit method was used to calculate the median and 1‐, 2‐, and 3‐year overall survival (OS). Results: Brain metastases were observed in 47,546 (10.4%) of the 457,481 patients with NSCLC overall. The prevalence of brain metastases was much higher (26%) in patients with stage IV disease at presentation. On multivariate analysis, younger age, adenocarcinoma or large cell histology, tumor size > 3 cm, tumor grade ≥ II, and node‐positive disease were associated with brain metastases. The prevalence of brain metastases ranged from as low as 0.57% in patients with only 1 risk factor to as high as 22% in patients with all 5 risk factors. The median and 1‐, 2‐, and 3‐year OS for patients with brain metastases were 6 months and 29.9%, 14.3%, and 8.4%, respectively, with the 3‐year OS increasing to 36.2% in those with T1/2 and N0/1 undergoing surgery for the primary site. Conclusions: In patients with NSCLC, the risk of brain metastases at presentation may be calculated based on 5 clinical variables. Selected patients with brain metastases at presentation may achieve prolonged benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066 · cited 1×
“This cutoff was chosen as the median age at diagnosis for lung cancer is 70 years.(12) All statistical tests were 2-sided, and P < .”
MethodGovindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845 · cited 1×
“007 common sites of distant metastasis including the brain, liver, adrenal glands, and bones.(2-4) Brainmetastases remain a significant problem in patients with lung cancer for several reasons.”
BackgroundSelf-citationSchouten, L. J., Rutten, J., Huveneers, H. A. M., & Twijnstra, A. (2002) · Cancer · doi:10.1002/cncr.10541 · Cited by 1,590 · cited 1×
“size and selection bias owing to the setting from which these patient samples are drawn.(8-10) Therefore, a large study examining the frequency of brain metastases and validation of previously described clinical risk factors, such as age, histology, and gender, may provide a better understanding of both the prevalence…”
BackgroundBrastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A., Jones, R. T., Van Allen, E. M., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0369 · Cited by 1,082 · cited 1×
“The molecular analysis of patientmatched paired primary lung and brain metastases has implicated several, including PI3K/AKT/mTOR, HER2/EGFR, and MAPK CDK pathways in driving brain metastases, which may be therapeutically targeted.(22,23) Several agents, including small molecule EGFRtyrosine kinase inhibitors and next…”
BackgroundGoldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 993 · cited 1×
“With the advent of immunotherapy and approval of pembrolizumab and nivolumab for the treatment of metastatic NSCLC, the intracranial activity of these agents is also being investigated.(24-26) Our study provides the most comprehensive clinical predictor data for the brain metastases at presentation and may serve as a…”
BackgroundDistribution of Brain Metastases
Delattre, J. Y., Krol, G., Thaler, H. T., & Posner, J. B. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520310047016 · Cited by 778 · cited 1×
“First, they are commonly observed, accounting for approximately one-half of all solid tumor metastases to the brain.(5,6) Second, there has been an apparent stage migration resulting from the availability of modern staging imaging modalities, such as positron emission tomography and magnetic resonance imaging (MRI), w…”
BackgroundMishima, S., Nozaki, Y., Mikami, S., Kihira, E., Iikura, M., Koketsu, R., Sugiyama, H., Masuda, T., Kaname, H., Egami, Y., et al. (2015) · Case Reports in Gastroenterology · doi:10.1159/000381140 · Cited by 631
Kazandjian, D., Suzman, D. L., Blumenthal, G., Mushti, S., He, K., Libeg, M., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0507 · Cited by 477 · cited 1×
“With the advent of immunotherapy and approval of pembrolizumab and nivolumab for the treatment of metastatic NSCLC, the intracranial activity of these agents is also being investigated.(24-26) Our study provides the most comprehensive clinical predictor data for the brain metastases at presentation and may serve as a…”
Background
Cited by
Goldberg, S. B., Schalper, K. A., Gettinger, S. N., Mahajan, A., Herbst, R. S., Chiang, A. C., Lilenbaum, R., Wilson, F. H., Omay, S. B., Yu, J. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30111-x · Cited by 539
Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00247-3 · Cited by 440
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 255
Metadata
- Authors
- Waqar, S. N., Samson, P. P., Robinson, C. G., Bradley, J., Devarakonda, S., Du, L., Govindan, R., Gao, F., Puri, V., & Morgensztern, D.
- Venue
- Clinical Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 19
- Issue
- 4
- Pages
- e373-e379
- ISSN
- 1525-7304 (ISSN-L)
- OpenAlex
- W2789821514
- Cited by
- 248
- References
- 22
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.